BioLineRx down 53% on end of BL-1020 CLARITY trial
This article was originally published in Scrip
Executive Summary
Israeli biopharma company BioLineRx saw its stock price cut by more than half on 20 March after the company said it would discontinue the Phase II/III CLARITY clinical trial for BL-1020 in the treatment of schizophrenia based on a planned interim analysis that showed the antipsychotic was not likely to meet the trial's primary efficacy endpoint.